> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel Votes Down Veru Covid Therapy
- URL: https://www.fdaweb.com/panel-votes-down-veru-covid-therapy/
- Published: 2022-11-09T12:00:00.000Z
- Updated: 2026-09-14T18:05:42.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153169

FDA’s Pulmonary-Allergy Drugs Advisory Committee 11/9 voted 8 to 5 to recommend against an emergency use authorization for Veru’s investigational prostate cancer drug VERU-111 (sabizabulin) and its use as a treatment for hospitalized adults with moderate to severe Covid-19 who are at high risk for acute respiratory distress syndrome.

Panel members agreed with FDA concerns raised in a [briefing document](https://www.fda.gov/media/162979/download?ref=fdaweb.com) released before the meeting. The agency reviewers said that while the single study submitted by Veru met its prespecified primary endpoint of all-cause mortality at Day 60, they noted it was quite small in size (204 patients) compared to other therapeutic programs for patients hospitalized with Covid-19\. They said uncertainties with the trial data include high placebo group mortality rate, baseline imbalances in standard-of-care therapies, and differences in hospitalization duration before trial enrollment, among other issues.